Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPIFIR: Epcoritamab in First Relapse Large B Cell Lymphoma
NCT07126236Phase 2Recruiting
- Sponsor
- GELTAMO
- Start
- Aug 2025
- Primary completion
- Dec 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by GELTAMO. Started Aug 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07126236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126236.